Trials / Completed
CompletedNCT03823339
A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates
A Multicenter Prospective Non-interventional Study Investigating the Treatment Effect of Xultophy® Intensification in a Real World Population With Type 2 Diabetes in United Arab Emirates
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to collect information on how Xultophy® works in patients with type 2 diabetes. The participants will get Xultophy® as prescribed to them by the study doctor. The study will last for about 26-34 weeks. The participants will be asked questions about their health and their diabetes treatment as part of their normal study doctor's appointment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Insulin degludec/liraglutide | Patients will be treated with Insulin degludec/liraglutide (Xultophy®) at the treating physician's discretion and independent from the decision to include the patient in the study. |
Timeline
- Start date
- 2019-01-29
- Primary completion
- 2020-12-14
- Completion
- 2020-12-14
- First posted
- 2019-01-30
- Last updated
- 2021-09-22
Locations
3 sites across 1 country: United Arab Emirates
Source: ClinicalTrials.gov record NCT03823339. Inclusion in this directory is not an endorsement.